-
Dyne reports cardiopulmonary benefits in Duchenne trial of z-rostudirsen in individuals amenable to skipping exon 51
As an early investor in Dyne Therapeutics, CureDuchenne is happy to share that new analyses
-
Long-term AGAMREE data indicates continued effectiveness with clinically meaningful safety advantages over classic corticosteroids
Santhera Pharmaceuticals announced results from the ongoing Guardian study in Duchenne, and showed that AGAMREE








